

Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Research Report 2023

https://marketpublishers.com/r/G5DFF7CE21C0EN.html

Date: December 2023 Pages: 100 Price: US\$ 2,900.00 (Single User License) ID: G5DFF7CE21C0EN

Abstracts

Fibroblast growth factor 2 (FGF2) belongs to the family of fibroblast growth factors (FGFs), and is a potent inducer involved in the processes of proliferation and differentiation of a wide variety of cells derived from mesoderm and neuroectoderm.

According to QYResearch's new survey, global Fibroblast Growth Factor Receptor 2 Inhibitor market is projected to reach US\$ 3180.2 million in 2029, increasing from US\$ 2012 million in 2022, with the CAGR of 6.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Fibroblast Growth Factor Receptor 2 Inhibitor market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive



to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Fibroblast Growth Factor Receptor 2 Inhibitor market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Advenchen Laboratories
Amgen
ArQule
Santa Cruz Biotechnology
AstraZeneca
AVEO Pharmaceuticals
Batu Biologics
Boehringer Ingelheim
Bristol-Myers Squibb Company
Celon Pharma
Debiopharm International
Eddingpharm
Eisai

Eli Lilly and Company



Hutchison MediPharma

Novartis

Principia Biopharma

Vichem Chemie Research

Segment by Type

ASP-5878

AZD-4547

BAY-1163877

CPL-043

Debio-1347

EDP-317

Others

Segment by Application

Clinic

Hospital

Others

By Region

North America



United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico



Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Fibroblast Growth Factor Receptor 2 Inhibitor report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Research Report 2023



Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type

1.2.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

- 1.2.2 ASP-5878
- 1.2.3 AZD-4547
- 1.2.4 BAY-1163877
- 1.2.5 CPL-043
- 1.2.6 Debio-1347
- 1.2.7 EDP-317
- 1.2.8 Others
- 1.3 Market by Application

1.3.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth by Application: 2018 VS 2022 VS 2029

- 1.3.2 Clinic
- 1.3.3 Hospital
- 1.3.4 Others
- 1.4 Study Objectives
- 1.5 Years Considered
- 1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Perspective (2018-2029)

2.2 Fibroblast Growth Factor Receptor 2 Inhibitor Growth Trends by Region

2.2.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Fibroblast Growth Factor Receptor 2 Inhibitor Historic Market Size by Region (2018-2023)

2.2.3 Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Region (2024-2029)

2.3 Fibroblast Growth Factor Receptor 2 Inhibitor Market Dynamics

- 2.3.1 Fibroblast Growth Factor Receptor 2 Inhibitor Industry Trends
- 2.3.2 Fibroblast Growth Factor Receptor 2 Inhibitor Market Drivers



2.3.3 Fibroblast Growth Factor Receptor 2 Inhibitor Market Challenges

2.3.4 Fibroblast Growth Factor Receptor 2 Inhibitor Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Players by Revenue

3.1.1 Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Players by Revenue (2018-2023)

3.1.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Players (2018-2023)

3.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Fibroblast Growth Factor Receptor 2 Inhibitor Revenue

3.4 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Concentration Ratio3.4.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Concentration Ratio(CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in 2022

3.5 Fibroblast Growth Factor Receptor 2 Inhibitor Key Players Head office and Area Served

3.6 Key Players Fibroblast Growth Factor Receptor 2 Inhibitor Product Solution and Service

3.7 Date of Enter into Fibroblast Growth Factor Receptor 2 Inhibitor Market

3.8 Mergers & Acquisitions, Expansion Plans

4 FIBROBLAST GROWTH FACTOR RECEPTOR 2 INHIBITOR BREAKDOWN DATA BY TYPE

4.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Historic Market Size by Type (2018-2023)

4.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Type (2024-2029)

5 FIBROBLAST GROWTH FACTOR RECEPTOR 2 INHIBITOR BREAKDOWN DATA BY APPLICATION

5.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Historic Market Size by Application (2018-2023)



5.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size
(2018-2029)
6.2 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2018-2023)
6.4 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2024-2029)
6.5 United States
6.6 Canada

7 EUROPE

7.1 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2018-2029)

7.2 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2018-2023)

7.4 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2024-2029)

- 7.5 Germany
- 7.6 France
- 7.7 U.K.
- 7.8 Italy
- 7.9 Russia
- 7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2018-2029)8.2 Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate byRegion: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2018-2023)



8.4 Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2024-2029)

- 8.5 China
- 8.6 Japan
- 8.7 South Korea
- 8.8 Southeast Asia
- 8.9 India
- 8.10 Australia

9 LATIN AMERICA

9.1 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2018-2029)

9.2 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2018-2023)

9.4 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2018-2029)

10.2 Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2018-2023)

10.4 Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Advenchen Laboratories



- 11.1.1 Advenchen Laboratories Company Detail
- 11.1.2 Advenchen Laboratories Business Overview

11.1.3 Advenchen Laboratories Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.1.4 Advenchen Laboratories Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.1.5 Advenchen Laboratories Recent Development

11.2 Amgen

- 11.2.1 Amgen Company Detail
- 11.2.2 Amgen Business Overview
- 11.2.3 Amgen Fibroblast Growth Factor Receptor 2 Inhibitor Introduction
- 11.2.4 Amgen Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)
- 11.2.5 Amgen Recent Development

11.3 ArQule

- 11.3.1 ArQule Company Detail
- 11.3.2 ArQule Business Overview
- 11.3.3 ArQule Fibroblast Growth Factor Receptor 2 Inhibitor Introduction
- 11.3.4 ArQule Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)
- 11.3.5 ArQule Recent Development
- 11.4 Santa Cruz Biotechnology
- 11.4.1 Santa Cruz Biotechnology Company Detail
- 11.4.2 Santa Cruz Biotechnology Business Overview
- 11.4.3 Santa Cruz Biotechnology Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.4.4 Santa Cruz Biotechnology Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.4.5 Santa Cruz Biotechnology Recent Development

- 11.5 AstraZeneca
- 11.5.1 AstraZeneca Company Detail
- 11.5.2 AstraZeneca Business Overview
- 11.5.3 AstraZeneca Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.5.4 AstraZeneca Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.5.5 AstraZeneca Recent Development

11.6 AVEO Pharmaceuticals

11.6.1 AVEO Pharmaceuticals Company Detail

11.6.2 AVEO Pharmaceuticals Business Overview



11.6.3 AVEO Pharmaceuticals Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.6.4 AVEO Pharmaceuticals Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.6.5 AVEO Pharmaceuticals Recent Development

11.7 Batu Biologics

11.7.1 Batu Biologics Company Detail

11.7.2 Batu Biologics Business Overview

11.7.3 Batu Biologics Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.7.4 Batu Biologics Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.7.5 Batu Biologics Recent Development

11.8 Boehringer Ingelheim

11.8.1 Boehringer Ingelheim Company Detail

11.8.2 Boehringer Ingelheim Business Overview

11.8.3 Boehringer Ingelheim Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.8.4 Boehringer Ingelheim Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.8.5 Boehringer Ingelheim Recent Development

11.9 Bristol-Myers Squibb Company

11.9.1 Bristol-Myers Squibb Company Company Detail

11.9.2 Bristol-Myers Squibb Company Business Overview

11.9.3 Bristol-Myers Squibb Company Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.9.4 Bristol-Myers Squibb Company Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.9.5 Bristol-Myers Squibb Company Recent Development

11.10 Celon Pharma

11.10.1 Celon Pharma Company Detail

11.10.2 Celon Pharma Business Overview

11.10.3 Celon Pharma Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.10.4 Celon Pharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.10.5 Celon Pharma Recent Development

11.11 Debiopharm International

11.11.1 Debiopharm International Company Detail

11.11.2 Debiopharm International Business Overview

11.11.3 Debiopharm International Fibroblast Growth Factor Receptor 2 Inhibitor Introduction



11.11.4 Debiopharm International Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.11.5 Debiopharm International Recent Development

11.12 Eddingpharm

11.12.1 Eddingpharm Company Detail

11.12.2 Eddingpharm Business Overview

11.12.3 Eddingpharm Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.12.4 Eddingpharm Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.12.5 Eddingpharm Recent Development

11.13 Eisai

11.13.1 Eisai Company Detail

11.13.2 Eisai Business Overview

11.13.3 Eisai Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.13.4 Eisai Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.13.5 Eisai Recent Development

11.14 Eli Lilly and Company

11.14.1 Eli Lilly and Company Company Detail

11.14.2 Eli Lilly and Company Business Overview

11.14.3 Eli Lilly and Company Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.14.4 Eli Lilly and Company Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.14.5 Eli Lilly and Company Recent Development

11.15 Hutchison MediPharma

11.15.1 Hutchison MediPharma Company Detail

11.15.2 Hutchison MediPharma Business Overview

11.15.3 Hutchison MediPharma Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.15.4 Hutchison MediPharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.15.5 Hutchison MediPharma Recent Development

11.16 Novartis

11.16.1 Novartis Company Detail

11.16.2 Novartis Business Overview

11.16.3 Novartis Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.16.4 Novartis Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)



11.16.5 Novartis Recent Development

11.17 Principia Biopharma

11.17.1 Principia Biopharma Company Detail

11.17.2 Principia Biopharma Business Overview

11.17.3 Principia Biopharma Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.17.4 Principia Biopharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.17.5 Principia Biopharma Recent Development

11.18 Vichem Chemie Research

11.18.1 Vichem Chemie Research Company Detail

11.18.2 Vichem Chemie Research Business Overview

11.18.3 Vichem Chemie Research Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.18.4 Vichem Chemie Research Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

11.18.5 Vichem Chemie Research Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

- 13.2 Disclaimer
- 13.3 Author Details



List Of Tables

LIST OF TABLES

Table 1. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate

by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of ASP-5878

Table 3. Key Players of AZD-4547

Table 4. Key Players of BAY-1163877

Table 5. Key Players of CPL-043

Table 6. Key Players of Debio-1347

Table 7. Key Players of EDP-317

Table 8. Key Players of Others

Table 9. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 10. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 11. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2018-2023) & (US\$ Million)

Table 12. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Region (2018-2023)

Table 13. Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 14. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Region (2024-2029)

Table 15. Fibroblast Growth Factor Receptor 2 Inhibitor Market Trends

Table 16. Fibroblast Growth Factor Receptor 2 Inhibitor Market Drivers

Table 17. Fibroblast Growth Factor Receptor 2 Inhibitor Market Challenges

Table 18. Fibroblast Growth Factor Receptor 2 Inhibitor Market Restraints

Table 19. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue by Players (2018-2023) & (US\$ Million)

Table 20. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Players (2018-2023)

Table 21. Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor as of 2022)

Table 22. Ranking of Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Companies by Revenue (US\$ Million) in 2022

Table 23. Global 5 Largest Players Market Share by Fibroblast Growth Factor Receptor



2 Inhibitor Revenue (CR5 and HHI) & (2018-2023) Table 24. Key Players Headquarters and Area Served Table 25. Key Players Fibroblast Growth Factor Receptor 2 Inhibitor Product Solution and Service Table 26. Date of Enter into Fibroblast Growth Factor Receptor 2 Inhibitor Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Type (2018-2023) & (US\$ Million) Table 29. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Type (2018-2023) Table 30. Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Type (2024-2029) & (US\$ Million) Table 31. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Type (2024-2029) Table 32. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Application (2018-2023) & (US\$ Million) Table 33. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Application (2018-2023) Table 34. Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Application (2024-2029) & (US\$ Million) Table 35. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Application (2024-2029) Table 36. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029 Table 37. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2018-2023) & (US\$ Million) Table 38. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2024-2029) & (US\$ Million) Table 39. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029 Table 40. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2018-2023) & (US\$ Million) Table 41. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2024-2029) & (US\$ Million) Table 42. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029 Table 43. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2018-2023) & (US\$ Million) Table 44. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by



Region (2024-2029) & (US\$ Million)

Table 45. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 46. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2018-2023) & (US\$ Million)

Table 47. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2024-2029) & (US\$ Million)

Table 48. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 49. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2018-2023) & (US\$ Million)

Table 50. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2024-2029) & (US\$ Million)

 Table 51. Advenchen Laboratories Company Detail

Table 52. Advenchen Laboratories Business Overview

Table 53. Advenchen Laboratories Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 54. Advenchen Laboratories Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)

Table 55. Advenchen Laboratories Recent Development

Table 56. Amgen Company Detail

- Table 57. Amgen Business Overview
- Table 58. Amgen Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 59. Amgen Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)

Table 60. Amgen Recent Development

Table 61. ArQule Company Detail

Table 62. ArQule Business Overview

Table 63. ArQule Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 64. ArQule Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business

(2018-2023) & (US\$ Million)

- Table 65. ArQule Recent Development
- Table 66. Santa Cruz Biotechnology Company Detail

Table 67. Santa Cruz Biotechnology Business Overview

Table 68. Santa Cruz Biotechnology Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 69. Santa Cruz Biotechnology Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)

Table 70. Santa Cruz Biotechnology Recent Development



- Table 71. AstraZeneca Company Detail
- Table 72. AstraZeneca Business Overview
- Table 73. AstraZeneca Fibroblast Growth Factor Receptor 2 Inhibitor Product
- Table 74. AstraZeneca Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor
- Business (2018-2023) & (US\$ Million)
- Table 75. AstraZeneca Recent Development
- Table 76. AVEO Pharmaceuticals Company Detail
- Table 77. AVEO Pharmaceuticals Business Overview
- Table 78. AVEO Pharmaceuticals Fibroblast Growth Factor Receptor 2 Inhibitor Product
- Table 79. AVEO Pharmaceuticals Revenue in Fibroblast Growth Factor Receptor 2
- Inhibitor Business (2018-2023) & (US\$ Million)
- Table 80. AVEO Pharmaceuticals Recent Development
- Table 81. Batu Biologics Company Detail
- Table 82. Batu Biologics Business Overview
- Table 83. Batu Biologics Fibroblast Growth Factor Receptor 2 Inhibitor Product
- Table 84. Batu Biologics Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor
- Business (2018-2023) & (US\$ Million)
- Table 85. Batu Biologics Recent Development
- Table 86. Boehringer Ingelheim Company Detail
- Table 87. Boehringer Ingelheim Business Overview
- Table 88. Boehringer Ingelheim Fibroblast Growth Factor Receptor 2 Inhibitor Product
- Table 89. Boehringer Ingelheim Revenue in Fibroblast Growth Factor Receptor 2
- Inhibitor Business (2018-2023) & (US\$ Million)
- Table 90. Boehringer Ingelheim Recent Development
- Table 91. Bristol-Myers Squibb Company Company Detail
- Table 92. Bristol-Myers Squibb Company Business Overview
- Table 93. Bristol-Myers Squibb Company Fibroblast Growth Factor Receptor 2 Inhibitor Product
- Table 94. Bristol-Myers Squibb Company Revenue in Fibroblast Growth Factor
- Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)
- Table 95. Bristol-Myers Squibb Company Recent Development
- Table 96. Celon Pharma Company Detail
- Table 97. Celon Pharma Business Overview
- Table 98. Celon Pharma Fibroblast Growth Factor Receptor 2 Inhibitor Product
- Table 99. Celon Pharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor
- Business (2018-2023) & (US\$ Million)
- Table 100. Celon Pharma Recent Development
- Table 101. Debiopharm International Company Detail
- Table 102. Debiopharm International Business Overview



Table 103. Debiopharm International Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 104. Debiopharm International Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)

Table 105. Debiopharm International Recent Development

Table 106. Eddingpharm Company Detail

Table 107. Eddingpharm Business Overview

Table 108. Eddingpharm Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 109. Eddingpharm Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)

Table 110. Eddingpharm Recent Development

Table 111. Eisai Company Detail

Table 112. Eisai Business Overview

Table 113. Eisai Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 114. Eisai Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business

(2018-2023) & (US\$ Million)

Table 115. Eisai Recent Development

Table 116. Eli Lilly and Company Company Detail

Table 117. Eli Lilly and Company Business Overview

Table 118. Eli Lilly and Company Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 119. Eli Lilly and Company Revenue in Fibroblast Growth Factor Receptor 2

Inhibitor Business (2018-2023) & (US\$ Million)

Table 120. Eli Lilly and Company Recent Development

Table 121. Hutchison MediPharma Company Detail

Table 122. Hutchison MediPharma Business Overview

Table 123. Hutchison MediPharma Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 124. Hutchison MediPharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)

Table 125. Hutchison MediPharma Recent Development

Table 126. Novartis Company Detail

Table 127. Novartis Business Overview

Table 128. Novartis Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 129. Novartis Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business

(2018-2023) & (US\$ Million)

Table 130. Novartis Recent Development

 Table 131. Principia Biopharma Company Detail

Table 132. Principia Biopharma Business Overview

Table 133. Principia Biopharma Fibroblast Growth Factor Receptor 2 Inhibitor Product



Table 134. Principia Biopharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)

Table 135. Principia Biopharma Recent Development

Table 136. Vichem Chemie Research Company Detail

 Table 137. Vichem Chemie Research Business Overview

Table 138. Vichem Chemie Research Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 139. Vichem Chemie Research Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023) & (US\$ Million)

Table 140. Vichem Chemie Research Recent Development

Table 141. Research Programs/Design for This Report

Table 142. Key Data Information from Secondary Sources

Table 143. Key Data Information from Primary Sources



List Of Figures

LIST OF FIGURES

Figure 1. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Type: 2022 VS 2029

Figure 3. ASP-5878 Features

Figure 4. AZD-4547 Features

Figure 5. BAY-1163877 Features

Figure 6. CPL-043 Features

Figure 7. Debio-1347 Features

Figure 8. EDP-317 Features

Figure 9. Others Features

Figure 10. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size

Comparison by Application (2023-2029) & (US\$ Million)

Figure 11. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Application: 2022 VS 2029

Figure 12. Clinic Case Studies

Figure 13. Hospital Case Studies

Figure 14. Others Case Studies

Figure 15. Fibroblast Growth Factor Receptor 2 Inhibitor Report Years Considered

Figure 16. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 17. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 18. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Region: 2022 VS 2029

Figure 19. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Players in 2022

Figure 20. Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor as of 2022)

Figure 21. The Top 10 and 5 Players Market Share by Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in 2022

Figure 22. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Share



by Country (2018-2029) Figure 24. United States Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 25. Canada Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 26. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 27. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Country (2018-2029) Figure 28. Germany Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 29. France Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 30. U.K. Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 31. Italy Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 32. Russia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 33. Nordic Countries Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 34. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 35. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Region (2018-2029) Figure 36. China Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 37. Japan Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 38. South Korea Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 39. Southeast Asia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 40. India Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 41. Australia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million) Figure 42. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million)



Figure 43. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Country (2018-2029)

Figure 44. Mexico Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Brazil Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Country (2018-2029)

Figure 48. Turkey Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 49. Saudi Arabia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 50. Advenchen Laboratories Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 51. Amgen Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 52. ArQule Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 53. Santa Cruz Biotechnology Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 54. AstraZeneca Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 55. AVEO Pharmaceuticals Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 56. Batu Biologics Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 57. Boehringer Ingelheim Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 58. Bristol-Myers Squibb Company Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 59. Celon Pharma Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 60. Debiopharm International Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 61. Eddingpharm Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 62. Eisai Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor



Business (2018-2023)

Figure 63. Eli Lilly and Company Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 64. Hutchison MediPharma Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 65. Novartis Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 66. Principia Biopharma Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 67. Vichem Chemie Research Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2018-2023)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed



I would like to order

Product name: Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Research Report 2023 Product link: <u>https://marketpublishers.com/r/G5DFF7CE21C0EN.html</u>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G5DFF7CE21C0EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970